Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2006-02-09
2009-08-04
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C544S090000, C544S092000
Reexamination Certificate
active
07569564
ABSTRACT:
Methods of using compounds which are progesterone receptor agonists for contraception and the treatment of progesterone-related maladies alone or in combination with an estrogen receptor agonist or progesterone receptor antagonist are provided. These compounds have the structure:wherein R1, R2, R3, R4, R5, and Q1are defined herein.
REFERENCES:
patent: 3526621 (1970-09-01), Bernardi
patent: 3635941 (1972-01-01), Weaver
patent: 3635964 (1972-01-01), Skorcz
patent: 3917592 (1975-11-01), Kobzina
patent: 4093730 (1978-06-01), Butti
patent: 4440785 (1984-04-01), Walsh
patent: 4518597 (1985-05-01), Narr et al.
patent: 4666913 (1987-05-01), Kuhla
patent: 4670566 (1987-06-01), Walsh
patent: 4721721 (1988-01-01), Kuhla
patent: 4792561 (1988-12-01), Walker
patent: 4822794 (1989-04-01), Spada
patent: 4831027 (1989-05-01), Narr
patent: 4853473 (1989-08-01), Fischer
patent: 5007952 (1991-04-01), Kume
patent: 5171851 (1992-12-01), Kim
patent: 5414088 (1995-05-01), Von Der Saal
patent: 5447928 (1995-09-01), Williams
patent: 5453516 (1995-09-01), Fischer
patent: 5475020 (1995-12-01), Johnson
patent: 5519021 (1996-05-01), Young
patent: 5521166 (1996-05-01), Grubb
patent: 5659046 (1997-08-01), Kameswaran
patent: 5681817 (1997-10-01), Hodgen
patent: 5688808 (1997-11-01), Jones
patent: 5688810 (1997-11-01), Jones
patent: 5693646 (1997-12-01), Jones
patent: 5693647 (1997-12-01), Jones
patent: 5696127 (1997-12-01), Jones
patent: 5696130 (1997-12-01), Jones
patent: 5696133 (1997-12-01), Jones
patent: 5719136 (1998-02-01), Chwalisz
patent: 5733902 (1998-03-01), Schneider
patent: 5808139 (1998-09-01), Pathirana
patent: 5874430 (1999-02-01), Christ
patent: 6077840 (2000-06-01), Kurihara
patent: 6306851 (2001-10-01), Santilli
patent: 6319912 (2001-11-01), Grubb
patent: 6329416 (2001-12-01), Grubb
patent: 6339098 (2002-01-01), Collins
patent: 6355648 (2002-03-01), Fensome
patent: 6358947 (2002-03-01), Zhi
patent: 6358948 (2002-03-01), Zhang
patent: 6369056 (2002-04-01), Zhang
patent: 6380178 (2002-04-01), Grubb
patent: 6380235 (2002-04-01), Zhang
patent: 6391907 (2002-05-01), Fensome
patent: 6399593 (2002-06-01), Grubb
patent: 6407101 (2002-06-01), Collins et al.
patent: 6417214 (2002-07-01), Ullrich
patent: 6423699 (2002-07-01), Grubb
patent: 6436929 (2002-08-01), Zhang
patent: 6441019 (2002-08-01), Zhang
patent: 6444668 (2002-09-01), Grubb
patent: 6462032 (2002-10-01), Grubb
patent: 6498154 (2002-12-01), Grubb
patent: 6503939 (2003-01-01), Grubb
patent: 6509334 (2003-01-01), Zhang et al.
patent: 6521657 (2003-02-01), Fensome
patent: 6544970 (2003-04-01), Grubb
patent: 6562857 (2003-05-01), Collins
patent: 6566358 (2003-05-01), Zhang
patent: 6566372 (2003-05-01), Zhi
patent: 6608068 (2003-08-01), Fensome
patent: 6693103 (2004-02-01), Zhang
patent: 6713478 (2004-03-01), Zhang et al.
patent: 6759408 (2004-07-01), Grubb
patent: 6794373 (2004-09-01), Grubb
patent: 6835744 (2004-12-01), Ullrich
patent: 6841568 (2005-01-01), Fensome
patent: 6946454 (2005-09-01), Fensome
patent: 6964973 (2005-11-01), Zhi
patent: 6982261 (2006-01-01), Collins
patent: 2002/0111355 (2002-08-01), Zhang
patent: 2002/0115853 (2002-08-01), Zhang
patent: 2003/0092711 (2003-05-01), Zhang
patent: 2003/0220388 (2003-11-01), Ullrich
patent: 2004/0002535 (2004-01-01), Fensome
patent: 2004/0006060 (2004-01-01), Fensome
patent: 2004/0006122 (2004-01-01), Fensome
patent: 2004/0014798 (2004-01-01), Fensome
patent: 2004/0186101 (2004-09-01), Zhang
patent: 2005/0054711 (2005-03-01), Fensome
patent: 2005/0171186 (2005-08-01), Fensome
patent: 2005/0256110 (2005-11-01), Collins
patent: 3633861 (1988-04-01), None
patent: 4330234 (1995-03-01), None
patent: 4344463 (1995-06-01), None
patent: 022317 (1981-01-01), None
patent: 208510 (1987-01-01), None
patent: 311135 (1989-04-01), None
patent: 0166533 (1990-04-01), None
patent: 385850 (1990-09-01), None
patent: 483077 (1991-09-01), None
patent: 454330 (1991-10-01), None
patent: 535529 (1992-09-01), None
patent: 510235 (1992-10-01), None
patent: 947507 (1999-10-01), None
patent: 978279 (2000-02-01), None
patent: 63112584 (1988-05-01), None
patent: 95107403 (1996-11-01), None
patent: 2130020 (1999-05-01), None
patent: 2134262 (1999-08-01), None
patent: WO-86/03749 (1986-07-01), None
patent: WO-91/04974 (1991-04-01), None
patent: WO-91/06545 (1991-05-01), None
patent: WO-93/12085 (1993-06-01), None
patent: WO-94/14434 (1994-07-01), None
patent: WO-94/29272 (1994-12-01), None
patent: WO-95/11013 (1995-04-01), None
patent: WO-95/20389 (1995-08-01), None
patent: WO-95/20972 (1995-08-01), None
patent: WO-95/33746 (1995-12-01), None
patent: WO-96/15794 (1996-05-01), None
patent: WO-96/19458 (1996-06-01), None
patent: WO-96/19997 (1996-07-01), None
patent: WO-97/13767 (1997-04-01), None
patent: WO-97/49407 (1997-12-01), None
patent: WO-98/14436 (1998-04-01), None
patent: WO-98/27059 (1998-06-01), None
patent: WO-98/55116 (1998-12-01), None
patent: WO-99/10325 (1999-03-01), None
patent: WO-99/11264 (1999-03-01), None
patent: WO-99/15500 (1999-04-01), None
patent: WO-99/44608 (1999-09-01), None
patent: WO-01/15108 (2001-03-01), None
Collins et al., “Novel Pyrrole-Containing Progesterone Receptor Modulators”, Bioorg. Med. Chem. Lett., 14:2185 (2004), pp. 2185-2189.
Zhang et al., “6-Aryl-1,4-dihydro-benzo[d][1,3]oxazin-2-ones: A Novel Class of Potent, Selective, and Orally Active Nonsteroidal Progesterone Receptor Antagonists”, J. Med. Chem., 45(20):4379 (Aug. 27, 2002), pp. 4379-4382.
R. Evans, “The Steroid and Thyroid Hormone Receptor Superfamily”, Science, 240:889 (May 13, 1988).
A. Ulmann et al, “Clinical Uses of Mifepristone (MFP)”, Ann. N.Y. Acad. Sci., 261:248 (Jun. 12, 1995).
R. Kekkonen et al, “Sequential Regiment of the Antiprogesterone RU486 and Synthetic Progestin for Contraception”, Fertility and Sterility, 60(4):610 (Oct. 1993).
K. Horwitz et al, “Progestin, Progesterone Receptors, and Breast Cancer”, Horm. Cancer, publisher: Birkhaeuser, Boston, Mass., ed. Vedeckis, pp. 283-306 (1996) (abstract only).
A. Murphy et al, “Regression of Uterine Leiomyomata in Response to the Antiprogesterone RU486”, J. Clin. Endo. Metab., 76(2):513 (Feb. 1993).
L. Kettel et al, “Endocrine Responses to Long-Term Administration of the Antiprogesterone RU486 in Patients with Pelvic Endometriosis”, Fertility and Sterility, 56(3):402 (Sep. 1991).
H. Michna et al, “Differentiation Therapy with Progesterone Antagonists”, Ann. N.Y. Acad. Sci., 761:224 (Jun. 1995).
L. Zhi et al, “5-Aryl-1,2-Dihydrochromeno[3,4-f]quinolines: A Novel Class of Nonsteroidal Human Progesterone Receptor Agonists”, J. Med. Chem., 41(3):291 (Oct. 22, 1998).
D. Combs et al, “Nonsteroidal Progesterone Receptor Ligands. 2. High-Affinity Ligands with Selectivity for Bone Cell Progesterone Receptors”, J. Med. Chem., 38:4880 (Dec. 8, 1995).
K. Perlman et al, “20-Oxopregnacalciferols: Vitamin D Compounds that Bind the Progesterone Receptor”, Tet. Letters, 35(15):2295 (1994).
L. Hamann et al, “Synthesis and Biological Activity of Novel Nonsteroidal Progesterone Receptor Antagonists”, Ann. N.Y. Acad. Sci., 761:383 (Jun. 12, 1995).
R. Chen et al, “Synthesis and SAR of a Novel Series of Spirobenzothlzaepine Derivatives with Antiprogestin Activity”, POI-37, 16thInt. Cong. Het. Chem., Montana (1997).
B. Narr et al, “Preparation, Testing, and Formulation of Imidazobenzoxazinones as Cardiotonics”, Chemical Abstracts, 109:22973 (1988).
R. Hartmann et al, “Effects of Brofoxine, A New Anxiolytic on Experimentally Induced Conflict in Rats”, Proc. West. Pharmacol. Soc., 21:51-55 (1978).
B. Singh et al, “Novel cAMP PDE III Inhibitor” Imidazo[4,5-b]pyridin-2(3H)-ones and Thiazolo[4,5-b]pyridin-2(3H)-ones and their Analogs, J. Med. Chem., 37:248 (Jan. 21, 1994).
A. Andreani et al, “Potential Antitumor Agents XVII (1). Cytotoxic Agents from Indole Derivatives and their Intermediates”, Acta. Pharm. Nord., 2(6):407 (1990).
Sakata et
Collins Mark A.
Edwards James P.
Fensome Andrew
Jones Todd K.
Tegley Christopher M.
Carango, Esq. Paul
Howson & Howson LLP
Truong Tamthom N
Wilson James O
Wyeth
LandOfFree
Cyclothiocarbamate derivatives as progesterone receptor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclothiocarbamate derivatives as progesterone receptor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclothiocarbamate derivatives as progesterone receptor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4110908